Abstract |
NEED FOR NEW CHEMOTHERAPEUTIC AGENTS: The use of 5-FU in combination with leucoverin (LV) in the treatment of advanced colorectal cancer has consistently provided antitumoral response. The antitumoral activity of the 5-FU/LV combination is associated with inhibition of thymidylate synthetase, an essential enzyme in pyrimidine de novo biosynthesis of thymidilates as precursors of DNA synthesis. However, dose-limiting toxicities and the limited impact on survival point to the need to develop new drugs and approaches to improve therapeutic efficacy and survival. CLINICAL RESULTS: COMBINATIONS: The best combination between DNA interaction drugs based on potentiation of DNA damage induced by thymidylate synthetase inhibitors and inhibition of DNA repair by DNA interactions remains to be evaluated.
|
Authors | B Paule, N Brion |
Journal | Presse medicale (Paris, France : 1983)
(Presse Med)
2000 May 27-Jun 3
Vol. 29
Issue 19
Pg. 1072-7
ISSN: 0755-4982 [Print] France |
Vernacular Title | Cancer colorectal métastatique: nouveautés thérapeutiques. |
PMID | 10874920
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Antineoplastic Agents
- Enzyme Inhibitors
- Topoisomerase I Inhibitors
- Oxidoreductases
- Dihydrouracil Dehydrogenase (NADP)
- Thymidylate Synthase
- Leucovorin
- Fluorouracil
|
Topics |
- Antimetabolites, Antineoplastic
(administration & dosage)
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Colonic Neoplasms
(drug therapy)
- Dihydrouracil Dehydrogenase (NADP)
- Enzyme Inhibitors
(administration & dosage)
- Fluorouracil
(administration & dosage)
- Humans
- Leucovorin
(administration & dosage)
- Oxidoreductases
(antagonists & inhibitors)
- Rectal Neoplasms
(drug therapy)
- Thymidylate Synthase
(antagonists & inhibitors)
- Topoisomerase I Inhibitors
|